Compare Nutanix Inc (NTNX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs GeneDx Holdings Corp — how do they compare? Nutanix Inc trades at $54 (market cap $14.90B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Nutanix Inc is far larger — about 8.3× GeneDx Holdings Corp's market cap, and Nutanix Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| NTNX | WGS | |
|---|---|---|
Market Cap | $14.90B | $1.80B |
Sector | Technology | Technology |
52-Week High | $81.12 | $167.51 |
52-Week Low | $34.41 | $34.51 |
Enterprise Value | $14.41B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $55.11, up slightly by 0.05% today, with a bullish technical trend and strong analyst support. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $0.47 exceeding expectations. Revenue growth is projected to rise from $2.54 billion in 2025 to $2.7 billion in 2026, while net income margin improves to 10.03%. Recent news highlights partnerships and NVIDIA certification for its storage solutions, reinforcing its hybrid cloud positioning.
The outlook for NTNX is positive, driven by earnings momentum and strategic initiatives in AI infrastructure. Investment opportunities include potential upside to the $57.80 consensus price target and expanding profit margins. Key risks involve competitive pressures in cloud computing and reliance on enterprise spending cycles, which could impact growth if macroeconomic conditions weaken.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
